The Efficacy and Safety of Roxadustat for Anemia in Hemodialysis Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials
This meta-analysis demonstrated that roxadustat outperformed ESAs in enhancing SI, transferrin, and TIBC levels while also decreasing CRP levels. Roxadustat was not inferior to ESAs in terms of improving Hb levels and safety. These findings suggest that roxadustat was well tolerated and a potent alternative to ESAs in managing anemia among patients suffering from CKD and undergoing HD.
Authors
- Hailan Cui
- Weijing Liu (ORCID: https://orcid.org/0000-0003-0593-5983)
- Zijing Cao
- Yunling Geng
- Zhaocheng Dong (ORCID: https://orcid.org/0000-0003-0895-7168)
- Yuning Liu (ORCID: https://orcid.org/0000-0002-9441-9667)
- Jingyi Tang (ORCID: https://orcid.org/0000-0001-5560-1223)
- Shuaixing Zhang
Institutions
- Beijing University of Chinese Medicine (CN)
- Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine (CN)
- Beijing Hospital of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Toxics
- Published
- 2024-11-25
- DOI
- https://doi.org/10.3390/toxics12120846
- Citations
- 3
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.36
Funders
- National Natural Science Foundation of China